EL: Smart Eyewear Adoption And Expanded Markets Will Support Future Upside

Analysts have trimmed their price targets on EssilorLuxottica Société anonyme, with our updated fair value estimate moving from about €316 to €282. This reflects slightly lower revenue growth, a modestly softer profit margin profile and a reduced future P/E assumption, alongside recent cuts from major brokers to around €225 and below prior levels.

Analyst Commentary

Bullish Takeaways

Bullish analysts continue to see upside in EssilorLuxottica shares even after price target reductions, which suggests they still view the current valuation as reasonable relative to the company’s earnings profile.
The maintenance of an Overweight stance alongside a lower target implies confidence that the company can execute on its plan, even if expectations around future profit margins and P/E multiples are now more restrained.
Supportive views point to an underlying belief that the business model and market position can justify a premium valuation over time, provided revenue growth and profitability stay on track with revised assumptions.
Recent initiations with a neutral stance, rather than a negative one, indicate that some analysts are willing to give EssilorLuxottica time to prove execution, rather than assuming a material deterioration in the investment case.

Bearish Takeaways

Bearish analysts have marked down price targets sharply, for example from about €315 to €225, signalling more caution on how much investors should be willing to pay for the stock relative to earnings.
Target cuts of €50 and €85, including from major houses such as Goldman Sachs, point to concerns around the durability of prior growth assumptions and the level of margins that can be sustained.
Lower targets are consistent with a more conservative stance on execution risk, where even modest shortfalls on revenue or profitability could limit valuation support at previous P/E multiples.
The clustering of target reductions across multiple brokers suggests a more cautious consensus forming around the stock, which may keep expectations in check until there is clearer evidence on growth and margin delivery.

What's in the News

EssilorLuxottica and Meta reported that their Ray-Ban AI glasses partnership sold more than 7 million AI integrated frames in 2025, highlighting broad consumer adoption of smart eyewear, source: The Smart Glasses Gold Rush Is Leaving Old-School Eyewear Behind, 24 May 2026.
Commentary around the smart glasses market indicates that large technology platforms controlling software ecosystems, such as Alphabet and Samsung, are currently viewed as capturing more value than hardware focused eyewear brands, as hardware faces commoditization and margin pressure, source: The Smart Glasses Gold Rush Is Leaving Old-School Eyewear Behind, 24 May 2026.
EssilorLuxottica and Meta announced an expanded AI glasses portfolio, including new prescription friendly Ray-Ban Meta Blayzer Optics (Gen 2) and Scriber Optics (Gen 2) frames with a slimmer, more customizable design and a dedicated Meta AI action button.
The Ray-Ban Meta and Oakley Meta ranges are set to reach additional markets such as Japan, South Korea, Singapore, several Latin American countries and more, alongside new colorways and lens options including Transitions lenses paired with Oakley Prizm technology.
EssilorLuxottica’s general meeting approved a €4.00 per share dividend for the 2025 financial year, with an option for shareholders to receive the dividend in shares at a subscription price of €175.06 and payment scheduled for 3 June 2026.

Valuation Changes

Fair Value was reduced from about €316.45 to about €282.39, reflecting a cut of roughly 10.8% in the updated estimate.
The Discount Rate was adjusted slightly lower from about 7.41% to about 7.35%, implying a modestly lower required return in the model.
Revenue Growth eased from about 9.93% to about 9.33%, signalling a slightly more cautious stance on € revenue expansion assumptions.
The Net Profit Margin moved from about 9.87% to about 9.78%, indicating a small reduction in expected profitability on € earnings.
The Future P/E was brought down from about 49.22x to about 44.97x, pointing to a less generous valuation multiple applied to forecast earnings.

2 views

Key Takeaways

Ongoing innovation in vision solutions and smart eyewear, along with strategic acquisitions, enhances competitive advantage and supports future market share and profitability.
Global expansion, supply chain diversification, and direct-to-consumer initiatives drive top-line growth, operational resilience, and recurring revenue opportunities.
Heavy investment in innovative eyewear and premium segments exposes EssilorLuxottica to technology, regulatory, economic, and margin risks amid intensifying competition and global cost pressures.

Catalysts

About EssilorLuxottica Société anonyme

Designs, manufactures, and distributes ophthalmic lenses, frames, and sunglasses in North America, the Middle East, Africa, Europe, Latin America, and the Asia-Pacific.What are the underlying business or industry changes driving this perspective?

Strong pipeline of innovation in myopia management solutions (Stellest 2.0, DOT technology) and leadership in addressing rising vision disorders among children globally positions EssilorLuxottica to capture outsized growth from increasing myopia incidence, directly supporting future revenue and market share gains.
Expanding global presence, especially in Asia and Latin America, leverages the growing middle class and improved healthcare access in emerging markets, opening new high-growth channels and supporting sustained top-line expansion.
Investments in smart eyewear, AI-enabled vision solutions, and MedTech (Ray-Ban Meta, Oakley Meta, Nuance Audio, acquisition of Optegra Eye Clinics) capitalize on long-term demand for technologically advanced and personalized eye health platforms, catalyzing product mix upgrades and higher ASPs, which will benefit gross margin and future earnings.
Ongoing vertical integration and supply chain diversification (new production facilities in France, Thailand, Laos, Mexico) improve operational efficiency and mitigate tariff/regulatory headwinds, preserving or expanding operating margins and providing resilience to exogenous shocks.
Accelerating direct-to-consumer and subscription-based channels (notably in Europe and North America), plus deeper engagement with healthcare professionals, enable stronger customer acquisition, higher recurring revenues, and long-term margin improvement, supporting net income and cash flow growth.

EssilorLuxottica Société anonyme Earnings and Revenue Growth

EssilorLuxottica Société anonyme Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming EssilorLuxottica Société anonyme's revenue will grow by 9.3% annually over the next 3 years.
Analysts assume that profit margins will increase from 8.1% today to 9.8% in 3 years time.
Analysts expect earnings to reach €3.6 billion (and earnings per share of €7.79) by about June 2029, up from €2.3 billion today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as €4.7 billion.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 45.0x on those 2029 earnings, up from 34.3x today. This future PE is greater than the current PE for the GB Medical Equipment industry at 24.3x.
Analysts expect the number of shares outstanding to grow by 0.44% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.35%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

The rapid shift towards disruptive optical technologies, such as smart eyewear and AI-enabled glasses, carries substantial execution and adoption risks-if EssilorLuxottica is unable to maintain product relevance, successfully commercialize innovations, or keep pace with technology leaders, it could suffer from slower revenue growth and margin dilution, especially as wearables have been acknowledged as margin dilutive despite their sales momentum.
Intensifying global tariff headwinds and persistent inflationary pressures (notably in the U.S. market) could erode gross margins and net income, with recent results already showing 80-90 basis points of margin dilution and management warning that mitigation strategies like price increases and supply chain relocation may only gradually offset these costs.
The company's aggressive investment in MedTech and a growing assortment of premium/luxury segments (e.g., AI glasses, Stellest lenses, hearing aid eyewear) could make it increasingly vulnerable to economic downturns and cyclical spending contractions, thus exposing revenues and profitability to swings in discretionary consumer income and global macro risks.
EssilorLuxottica's reliance on being the market leader in emerging medical and wearable categories heightens its exposure to tightening regulatory scrutiny and slow or fragmented reimbursement/approval processes (e.g., FDA approval for Stellest lenses), potentially delaying new revenue streams and pressuring earnings if regulatory hurdles or commercialization setbacks occur.
The ongoing expansion of integrated, direct-to-consumer channels and major retail rollouts raises the risk of operational complexity and execution missteps, while at the same time global e-commerce and lower-cost competitors are driving greater price transparency and margin compression-pressuring EssilorLuxottica's long-term revenue growth and its ability to sustain premium pricing.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of €282.39 for EssilorLuxottica Société anonyme based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of €361.0, and the most bearish reporting a price target of just €180.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be €37.2 billion, earnings will come to €3.6 billion, and it would be trading on a PE ratio of 45.0x, assuming you use a discount rate of 7.3%.
Given the current share price of €172.8, the analyst price target of €282.39 is 38.8% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on EssilorLuxottica Société anonyme?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

EL: Expansion Into New Optical Markets Will Drive Measured MedTech Momentum